Correlation Between Spyre Therapeutics and Foremost Lithium

Can any of the company-specific risk be diversified away by investing in both Spyre Therapeutics and Foremost Lithium at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Spyre Therapeutics and Foremost Lithium into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Spyre Therapeutics and Foremost Lithium Resource, you can compare the effects of market volatilities on Spyre Therapeutics and Foremost Lithium and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Spyre Therapeutics with a short position of Foremost Lithium. Check out your portfolio center. Please also check ongoing floating volatility patterns of Spyre Therapeutics and Foremost Lithium.

Diversification Opportunities for Spyre Therapeutics and Foremost Lithium

0.57

Correlation Coefficient

Spyre Therapeutics  Foremost Lithium

Very weak diversification

The 3 months correlation between Spyre and Foremost is 0.57. Overlapping area represents the amount of risk that can be diversified away by holding Spyre Therapeutics and Foremost Lithium Resource in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Foremost Lithium Resource and Spyre Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Spyre Therapeutics are associated (or correlated) with Foremost Lithium. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Foremost Lithium Resource has no effect on the direction of Spyre Therapeutics i.e., Spyre Therapeutics and Foremost Lithium go up and down completely randomly.

Pair Corralation between Spyre Therapeutics and Foremost Lithium

Given the investment horizon of 90 days Spyre Therapeutics is expected to under-perform the Foremost Lithium. But the stock apears to be less risky and, when comparing its historical volatility, Spyre Therapeutics is 3.87 times less risky than Foremost Lithium. The stock trades about -0.1 of its potential returns per unit of risk. The Foremost Lithium Resource is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest  120.00  in Foremost Lithium Resource on December 20, 2024 and sell it today you would lose (57.00) from holding Foremost Lithium Resource or give up 47.5% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Spyre Therapeutics  vs.  Foremost Lithium Resource

Spyre Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Spyre Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Foremost Lithium Resource

Risk-Adjusted Performance

Very Weak

Over the last 90 days Foremost Lithium Resource has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Pair Trading with Spyre Therapeutics and Foremost Lithium

The main advantage of trading using opposite Spyre Therapeutics and Foremost Lithium positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Spyre Therapeutics position performs unexpectedly, Foremost Lithium can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Foremost Lithium will offset losses from the drop in Foremost Lithium's long position.

The idea behind Spyre Therapeutics and Foremost Lithium Resource pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .